Literature DB >> 21497452

Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.

Hugo Villeneuve1, Philippe Després, Bernard Fortin, Edith Filion, David Donath, Denis Soulières, Louis Guertin, Tarek Ayad, Apostolos Christopoulos, Phuc Felix Nguyen-Tan.   

Abstract

PURPOSE: To determine the effectiveness and rate of complications of intensity-modulated radiotherapy (IMRT) in the treatment of cervical lymph node metastases from unknown primary cancer. METHODS AND MATERIALS: Between February 2005 and November 2008, 25 patients with an unknown primary cancer underwent IMRT, with a median radiation dose of 70 Gy. The bilateral neck and ipsilateral putative pharyngeal mucosa were included in the target volume. All patients had squamous cell carcinoma, except for 1 patient who had adenosquamous differentiation. They were all treated with curative intent. Of the 25 included patients, 20 were men and 5 were women, with a median age of 54 years. Of these patients, 3 had Stage III, 18 had Stage IVa, and 4 had Stage IVb. Of the 25 patients, 18 (72%) received platinum-based chemotherapy in a combined-modality setting. Neck dissection was reserved for residual disease after definitive IMRT. Overall survival, disease-free survival, and locoregional control were calculated using the Kaplan-Meier method.
RESULTS: With a median follow-up of 38 months, the overall survival, disease-free survival, and locoregional control rates were all 100% at 3 years. No occurrence of primary cancer was observed during the follow-up period. The reported rates of xerostomia reduced with the interval from the completion of treatment. Nine patients (36%) reported Grade 2 or greater xerostomia at 6 months, and only 2 (8%) of them reported the same grade of salivary function toxicity after 24 months of follow-up.
CONCLUSION: In our institution, IMRT for unknown primary cancer has provided good overall and disease-free survival in all the patients with an acceptable rate of complications. IMRT allowed us to address the bilateral neck and ipsilateral putative pharyngeal mucosa with minimal late salivary function toxicity. The use of concurrent chemotherapy and IMRT for more advanced disease led to good clinical results with reasonable toxicities. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21497452     DOI: 10.1016/j.ijrobp.2011.02.031

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Individualized IMRT treatment approach for cervical lymph node metastases of unknown primary.

Authors:  S Janssen; C Glanzmann; G Huber; G Studer
Journal:  Strahlenther Onkol       Date:  2014-02-07       Impact factor: 3.621

Review 2.  Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.

Authors:  Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

3.  Patterns of failure in patients with head and neck carcinoma of unknown primary treated with radiation therapy.

Authors:  John Cuaron; Shyam Rao; Suzanne Wolden; Michael Zelefsky; Karen Schupak; Borys Mychalczak; Nancy Lee
Journal:  Head Neck       Date:  2015-07-06       Impact factor: 3.147

4.  Inter-observer variability of clinical target volume delineation in definitive radiotherapy of neck lymph node metastases from unknown primary. A cooperative study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Head and Neck Group.

Authors:  Marianna Trignani; Angela Argenone; Saide Di Biase; Daniela Musio; Anna Merlotti; Stefano Ursino; Ester Orlandi; Domenico Genovesi; Almalina Bacigalupo
Journal:  Radiol Med       Date:  2019-03-09       Impact factor: 3.469

5.  Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival.

Authors:  Miloslav Pala; Pavla Novakova; Zdena Pechacova; Lucie Vesela; Antonin Vrana; Jarmila Sukova; Petra Holeckova; Tereza Drbohlavova; Tomas Podlesak; Lubos Petruzelka
Journal:  Strahlenther Onkol       Date:  2022-08-09       Impact factor: 4.033

6.  Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group.

Authors:  Anna Merlotti; Daniela Alterio; Riccardo Vigna-Taglianti; Alessandro Muraglia; Luciana Lastrucci; Roberto Manzo; Giuseppina Gambaro; Orietta Caspiani; Francesco Miccichè; Francesco Deodato; Stefano Pergolizzi; Pierfrancesco Franco; Renzo Corvò; Elvio G Russi; Giuseppe Sanguineti
Journal:  Radiat Oncol       Date:  2014-12-29       Impact factor: 3.481

7.  Current advances in diagnosis and surgical treatment of lymph node metastasis in head and neck cancer.

Authors:  A Teymoortash; J A Werner
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20

8.  Cervical squamous cell lymph node metastases from an unknown primary site: survival and patterns of recurrence after radiotherapy.

Authors:  Cihan Gani; Franziska Eckert; Arndt-Christian Müller; Paul-Stefan Mauz; John Thiericke; Michael Bamberg; Martin Weinmann
Journal:  Clin Med Insights Oncol       Date:  2013-08-04

9.  Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life.

Authors:  Alexander D Sherry; Dario Pasalic; G Brandon Gunn; C David Fuller; Jack Phan; David I Rosenthal; William H Morrison; Erich M Sturgis; Neil D Gross; Maura L Gillison; Renata Ferrarotto; Adel K El-Naggar; Adam S Garden; Steven J Frank
Journal:  Int J Part Ther       Date:  2021-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.